Douglas Holtzman - 13 Feb 2023 Form 4 Insider Report for Icosavax, Inc.

Role
Chief Scientific Officer
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
13 Feb 2023
Net transactions value
-$50,338
Form type
4
Filing time
15 Feb 2023, 19:07:58 UTC
Previous filing
16 Dec 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Sale $16,274 -1,522 -0.52% $10.69 293,403 13 Feb 2023 Direct F1, F2
transaction ICVX Common Stock Sale $34,064 -3,349 -1.1% $10.17 290,054 14 Feb 2023 Direct F3, F4
holding ICVX Common Stock 2,792 13 Feb 2023 By Stanley Holtzman F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $11.02. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2022.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.83 to $10.72. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Douglas Holtzman, Ph.D. holds power-of-attorney (POA) over the shares owned by Stanley Holtzman. As POA, Dr. Holtzman holds voting and dispositive control over such shares. Dr. Holtzman disclaims beneficial ownership of the shares over which he has POA except to the extent of any pecuniary interest therein.